Patents by Inventor Jill A. Panetta

Jill A. Panetta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20010018437
    Abstract: This invention provides novel thiomorpholinone compounds useful for treating multiple sclerosis.
    Type: Application
    Filed: August 27, 1999
    Publication date: August 30, 2001
    Inventors: JILL PANETTA, MICHAEL L. PHILLIPS
  • Patent number: 6251928
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Patent number: 5981523
    Abstract: This invention provides thiomorpholinone compounds useful for treating multiple sclerosis of formula I wherein:R.sup.1 and R.sup.2 are each independently selected from C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl; C.sub.2 -C.sub.8 alkynyl; C.sub.1 -C.sub.8 alkyloxy; C.sub.1 -C.sub.8 alkylthio; trifluoromethyl; C.sub.1 -C.sub.4 alkyl substituted with phenyl; phenyl; F; Cl; NO.sub.2 ; phenoxy; C.sub.1 -C.sub.4 alkyl substituted with phenoxy; thiophenyl; C.sub.1 -C.sub.4 alkylthiophenyl; --COOR.sup.7 ; --N(R.sup.7).sub.2 or --N(R.sup.7)SO.sub.2 R.sup.7 where each R.sup.7 is independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.3 is H or C.sub.1 -C.sub.4 alkyl;R.sup.4 and R.sup.5 are each individually H, or when taken together form a bond;R.sup.6 is H; C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl; C.sub.2 -C.sub.8 alkynyl; --SO.sub.2 CH.sub.3 ; --(CH.sub.2).sub.n NR.sup.8 R.sup.9 ; --(CH.sub.2).sub.n CO.sub.2 R.sup.8 ; --(CH.sub.2).sub.n OR.sup.8 where n is an integer from 1 to 6, both inclusive, and R.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Jill A Panetta, Michael L Phillips
  • Patent number: 5814646
    Abstract: A method of protecting a warm-blooded mammal from the progression of Alzheimer's disease, which comprises administering an effective amount of a compound of general formula. ##STR1## in which: R.sup.1 represents an optionally substituted aromatic or heteroaromatic group;L.sup.1 and L.sup.2 each independently represents a bond or an unbranched (1-4C) alkylene group, which alkylene group may optionally bear a (1-4C) alkyl, phenyl or phenyl (1-2C) alkyl substituent;one of Y.sup.1 and Y.sup.2 represents NR.sup.3 and the other represents O, S or NR.sup.3, in which R.sup.3 represent hydrogen, hydroxyl, (1-4C) alkoxy, (1-4C) alkyl or di (1-4C) alkylamino;Z represents O or S; andR.sup.2 represents (3-8C) cycloalkyl, heterocyclyl, and optionally substituted aromatic or heteroaromatic group, or together with L.sup.2, (1-10C) alkyl;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: September 29, 1998
    Assignee: Eli Lilly and Company
    Inventors: Lawrence J. Heinz, Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Richard L. Simon, Celia A. Whitesitt
  • Patent number: 5747517
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: May 5, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Patent number: 5731336
    Abstract: Provided is a method of treating multiple sclerosis employing certain aryl-substituted rhodanines.
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: March 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Ann E. Kingston, Jill A. Panetta
  • Patent number: 5716975
    Abstract: Provided are methods for treating hyperglycemia and Alzheimer's disease utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant methods are novel and, accordingly, such compounds and pharmaceutical formulations thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: Juliana M. Bue-Valleskey, David C. Hunden, Charles D. Jones, Jill A. Panetta, Walter N. Shaw
  • Patent number: 5691367
    Abstract: Provided are certain aryl-substituted rhodanine derivatives, treatment methods and pharmaceutical formulations thereof.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: November 25, 1997
    Assignee: Eli Lilly and Company
    Inventor: Jill A. Panetta
  • Patent number: 5674887
    Abstract: The administration of a xanthine oxidase inhibitor is effective for the treatment or prevention of the excessive resorption of bone in conditions such as osteoporosis and the like.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: October 7, 1997
    Assignees: Eli Lilly and Company, London Hospital Medical College, St. George's Hospital Medical School
    Inventors: David R. Blake, Jill A. Panetta, Mone Zaidi
  • Patent number: 5661168
    Abstract: Provided is a method for treating hyperglycemia utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant method are novel and, accordingly, such compounds and pharmaceutical formulations thereof, are also provided.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Juliana Bue-Valleskey, David C. Hunden, Charles D. Jones, Walter N. Shaw
  • Patent number: 5633283
    Abstract: Provided is a method of treating multiple sclerosis employing certain phenol and benzamide compounds.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: May 27, 1997
    Assignee: Eli Lilly and Company
    Inventors: Ann E. Kingston, Jill A. Panetta
  • Patent number: 5552439
    Abstract: Provided is a method for treating inflammatory bowel disease in mammals utilizing certain phenol and benzamide compounds.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventor: Jill A. Panetta
  • Patent number: 5523314
    Abstract: Provided are methods for treating hyperglycemia and Alzheimer's disease utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant methods are novel and, accordingly, such compounds and pharmaceutical formulations thereof are also provided.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: June 4, 1996
    Assignee: Eli Lilly and Company
    Inventors: Juliana M. Bue-Valleskey, David C. Hunden, Charles D. Jones, Jill A. Panetta, Walter N. Shaw
  • Patent number: 5476865
    Abstract: Rhodanine derivatives are utilized as inhibitors of bone loss/bone resorption and cartilage degradation.
    Type: Grant
    Filed: July 6, 1994
    Date of Patent: December 19, 1995
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Masahiko Sato
  • Patent number: 5441984
    Abstract: The present invention provides novel urea, thiourea and guanidine derivatives, pharmaceutical formulations thereof and a method of using same to prevent diabetic complications.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Jill A. Panetta, John K. Shadle
  • Patent number: 5436258
    Abstract: The administration of a xanthine oxidase inhibitor is effective for the treatment or prevention of the excessive resorption of bone in conditions such as osteoporosis and the like.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: July 25, 1995
    Assignees: Eli Lilly and Company, London Hospital Medical College, St. George's Hospital Medical School
    Inventors: David R. Blake, Jill A. Panetta, Mone Zaidi
  • Patent number: 5393786
    Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: February 28, 1995
    Assignee: Eli Lilly and Company
    Inventors: James A. Clemens, Jill A. Panetta
  • Patent number: 5387690
    Abstract: Provided is a method of treating inflammatory bowel disease in mammals utilizing certain benzyl-substituted rhodanine derivatives. Also provided are novel benzyl-substituted rhodanine derivatives and pharmaceutical compositions thereof, as well as a novel process for selectively isolating in substantially pure enantiomeric form the enantiomers of certain racemic benzyl-substituted rhodanine derivatives.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: February 7, 1995
    Assignee: Eli Lilly and Company
    Inventors: Jaswant S. Gidda, Jill A. Panetta, Michael L. Phillips
  • Patent number: 5356917
    Abstract: Provided are certain aryl-substituted rhodanine derivatives, treatment methods and pharmaceutical formulations thereof.
    Type: Grant
    Filed: August 24, 1993
    Date of Patent: October 18, 1994
    Assignee: Eli Lilly and Company
    Inventor: Jill A. Panetta
  • Patent number: 5294630
    Abstract: Inflammatory bowel disease is treated, and patients are protected from a relapse into active disease, by the administration of a compound chosen from a series of 3-phenyl-5-carboxypyrazoles and isothiazoles.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: March 15, 1994
    Assignees: Eli Lilly and Company, London Hospital Medical College
    Inventors: David Blake, Peter P. K. Ho, Jill A. Panetta, David Rampton, Nicola Simmonds